Clinical Trial Update: A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses (6 Days) of 100 mg Resmetirom in Subjects With Severe Renal Impairment and in Matched Healthy Control Subjects With Normal Renal Function [Phase 1]

View source ↗

Summary

This Phase 1 study evaluated pharmacokinetics, safety, and tolerability of six days of 100 mg resmetirom in adults with severe renal impairment compared to matc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Impairment

Drugs mentioned

• Resmetirom (resmetirom)

Snippet

Sponsor: Madrigal Pharmaceuticals, Inc. | Conditions: Renal Impairment | Phase 1 | Status: COMPLETED